Online inquiry

IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ512MR)

This product GTTS-WQ512MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IGHE gene. The antibody can be applied in Urticaria research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NC_000014.9
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3497
UniProt ID P01854
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ512MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4505MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-936557
GTTS-WQ10754MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA M-6495
GTTS-WQ405MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ5753MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ5528MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDP4940
GTTS-WQ8361MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA hPAM4
GTTS-WQ12410MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NI-0401
GTTS-WQ1271MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-414
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW